[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641577":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":44,"locations":53,"responsibleParty":70,"collaborators":73,"id":77,"slug":31,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":31,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":106,"whyStopped":31,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Shandong Provincial Hospital","OTHER_GOV",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Mazdutide 4 mg","EXPERIMENTAL","Mazdutide 2 mg once weekly subcutaneous injection for 4 weeks (titration), then 4 mg once weekly for 20 weeks. All participants receive standardized lifestyle intervention (dietary modification and aerobic exercise) throughout the 48-week study period.",[13,14],"Drug: Mazdutide","Behavioral: Standardized Lifestyle Intervention",{"label":16,"type":10,"description":17,"interventionNames":18},"Mazdutide 6 mg","Mazdutide 2 mg once weekly subcutaneous injection for 4 weeks, then 4 mg once weekly for 4 weeks, then 6 mg once weekly for 16 weeks. All participants receive standardized lifestyle intervention throughout the 48-week study period.",[13,14],{"label":20,"type":21,"description":22,"interventionNames":23},"Placebo","PLACEBO_COMPARATOR","Matching placebo once weekly subcutaneous injection. Placebo pens are identical to active drug pens in appearance, color, volume, and packaging. The titration schedule mirrors the 6 mg arm (weeks 0-4, 5-8, 9-24) to maintain blinding. All participants receive standardized lifestyle intervention throughout the 48-week study period.",[24,14],"Drug: Placebo",[26,32,35],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Mazdutide","GLP-1 receptor\u002Fglucagon receptor (GLP-1R\u002FGCGR) dual agonist, administered by subcutaneous injection once weekly using a pre-filled pen device. Arm 1 (4 mg): titration from 2 mg QW (weeks 0-4) to 4 mg QW (weeks 5-24). Arm 2 (6 mg): titration from 2 mg QW (weeks 0-4) to 4 mg QW (weeks 5-8) to 6 mg QW (weeks 9-24). Injection sites: abdomen, anterior-lateral thigh, or lateral upper arm, rotated at each injection.",[9,16],null,{"type":27,"name":20,"description":33,"armGroupLabels":34,"otherNames":31},"Matching placebo for mazdutide, administered by subcutaneous injection once weekly using a pre-filled pen device identical in appearance, color, volume, and packaging to the active drug pen. Titration schedule mirrors the 6 mg mazdutide arm to maintain blinding.",[20],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"BEHAVIORAL","Standardized Lifestyle Intervention","Structured dietary modification with an energy deficit of 500-750 kcal\u002Fday and moderate-intensity aerobic exercise of at least 150 minutes per week, maintained throughout the 48-week study period. Applied equally to all three arms.",[9,16,20],[41],{"name":42,"affiliation":5,"role":43},"Jiajun Zhao, MD, PhD","PRINCIPAL_INVESTIGATOR",[45,49],{"name":42,"role":46,"phone":47,"phoneExt":31,"email":48},"CONTACT","0531-68776025","jjzhao@sdu.edu.cn",{"name":50,"role":46,"phone":51,"phoneExt":31,"email":52},"Xiude Fan, MD, PhD","+8613186067538","fanxiudexjtu@163.com",[54],{"facility":55,"status":31,"city":56,"state":57,"zip":58,"country":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Shandong Provincial Hospital Affiliated to Shandong First Medical University","Jinan","Shandong","250021","China",{"type":61,"coordinates":62},"Point",[63,64],116.99722,36.66833,{"lat":64,"lon":63},[67,69],{"name":50,"role":46,"phone":68,"phoneExt":31,"email":52},"13186067538",{"name":42,"role":43,"phone":31,"phoneExt":31,"email":31},{"type":43,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Jia-jun Zhao","Professor, Chief Physician, Department of Endocrinology and Metabolic Disease",[74],{"name":75,"class":76},"Innovent Biologics, Inc.","OTHER","100641577",false,"NCT07654062","Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)","Efficacy and Safety of Mazdutide in Adults With Prediabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (DREAM-PRE)","DREAM-PRE","Inclusion Criteria:\n\n1. Voluntarily signed written informed consent prior to any study procedures\n2. Age 18 to 75 years (inclusive) at the time of signing informed consent; male or female\n3. Prediabetes confirmed by central laboratory at screening, meeting at least one of the following criteria per Chinese Diabetes Society (CDS) standards, and not meeting diagnostic criteria for diabetes:\n\n   * Impaired Glucose Tolerance (IGT): 75g OGTT 2-hour plasma glucose\n\n     * 7.8 mmol\u002FL and \\\u003C11.1 mmol\u002FL\n   * Impaired Fasting Glucose (IFG): fasting plasma glucose ≥6.1 mmol\u002FL and \\\u003C7.0 mmol\u002FL\n   * Elevated HbA1c: 5.7% ≤ HbA1c \\\u003C 6.5% (39-48 mmol\u002Fmol)\n4. BMI ≥22.0 kg\u002Fm² at screening\n5. Self-reported body weight change \\\u003C10% within 3 months prior to screening; not currently participating in any organized weight-loss program\n6. Able to understand study requirements, complete all planned visits and examinations, self-administer once-weekly subcutaneous injections, and use the study app for daily monitoring\n\nExclusion Criteria:\n\n1. Confirmed diabetes at screening (FPG ≥7.0 mmol\u002FL, OGTT 2h-PG ≥11.1 mmol\u002FL, or HbA1c ≥6.5%); or prior confirmed diagnosis of type 1 diabetes, type 2 diabetes, or other specific types of diabetes. Prior gestational diabetes in whom blood glucose has returned to prediabetes levels after delivery is NOT grounds for exclusion.\n2. Continuous use of any antidiabetic medication for more than 7 days within 3 months prior to screening, including: biguanides (metformin), alpha-glucosidase inhibitors (acarbose, voglibose, miglitol), sulfonylureas (glimepiride, gliclazide, glipizide, glibenclamide), glinides (repaglinide, nateglinide), thiazolidinediones (pioglitazone, rosiglitazone), DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin), SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ertugliflozin), insulin (any formulation), or traditional Chinese medicine with confirmed glucose-lowering indication.\n3. Use of any of the following within 6 months prior to screening (regardless of duration): GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, benaglutide, etc.), GIP\u002FGLP-1 dual agonists (tirzepatide, etc.), any dual or triple agonist containing GLP-1R and\u002For GCGR components (including mazdutide), or any GLP-1 class investigational drug in clinical development.\n4. Use of any prescription weight-loss medication within 3 months prior to screening (regardless of duration), including orlistat, naltrexone\u002Fbupropion combination, phentermine\u002Ftopiramate combination, or any weight-loss drug approved in China or in clinical development. Over-the-counter dietary supplements are not excluded but must be recorded.\n5. Spontaneous body weight change ≥10% within 3 months prior to screening (based on self-report and\u002For available medical records), or currently participating in any organized weight-loss program (including commercial weight-loss plans or weight-loss interventions in other clinical trials).\n6. Prior bariatric or metabolic surgery including Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding, biliopancreatic diversion, intragastric balloon placement, or other bariatric surgery.\n7. Prior history of acute pancreatitis (confirmed by imaging or surgery) or chronic pancreatitis; or serum amylase \\>3× ULN or serum lipase \\>3× ULN at screening.\n8. Personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2); first-degree family history of MTC or MEN2; or serum calcitonin ≥50 ng\u002FL at screening.\n9. Any of the following within 6 months prior to screening: acute myocardial infarction (STEMI or NSTEMI), ischemic or hemorrhagic stroke, transient ischemic attack (TIA), coronary revascularization (PCI or CABG), or hospitalization for unstable angina.\n10. NYHA Class III or IV heart failure. (NYHA Class I and II are not grounds for exclusion.)\n11. Clinically significant arrhythmia on 12-lead ECG at screening, including:\n\n    Mobitz Type II or third-degree atrioventricular block, sustained ventricular tachycardia (≥30 seconds or requiring cardioversion), QTcF \\>500 ms, or resting heart rate \\\u003C50 bpm (in subjects not using beta-blockers or calcium channel blockers).\n12. Uncontrolled hypertension: confirmed mean systolic blood pressure ≥180 mmHg and\u002For mean diastolic blood pressure ≥110 mmHg on repeated measurements at screening despite antihypertensive therapy. Subjects with controlled blood pressure on a stable antihypertensive regimen (stable for ≥4 weeks prior to screening) are allowed to enroll.\n13. ALT \\>3× ULN, AST \\>3× ULN, or total bilirubin \\>2× ULN at screening (except confirmed Gilbert's syndrome with normal direct bilirubin).\n14. eGFR (CKD-EPI) \\\u003C45 mL\u002Fmin\u002F1.73 m² at screening. Subjects with eGFR 45-60 mL\u002Fmin\u002F1.73 m² may enroll with enhanced renal function monitoring.\n15. Any of the following gastrointestinal conditions: known gastroparesis (confirmed by gastric emptying study or clinical diagnosis), inflammatory bowel disease (Crohn's disease or ulcerative colitis, active or remission), short bowel syndrome, prior gastrointestinal surgery likely to affect drug absorption (excluding simple appendectomy and laparoscopic cholecystectomy), or other serious gastrointestinal disease likely to significantly affect drug tolerability or absorption.\n16. Diagnosis or active treatment of any malignancy within 5 years prior to screening.\n17. Positive urine pregnancy test at screening, currently breastfeeding, or planning pregnancy during the 48-week study period.\n18. Known allergy to mazdutide or any excipient in its formulation; or prior serious allergic reaction to any GLP-1 class drug (defined as angioedema, anaphylactic shock, or allergic reaction requiring hospitalization).\n19. Participation in any other interventional clinical trial within 3 months prior to screening (excluding purely observational or epidemiological studies not involving investigational drugs or devices), or currently enrolled in any other clinical trial.\n20. Currently on long-term systemic corticosteroids (expected continuous use \\>14 days, oral or intravenous); or currently using drugs known to significantly affect body weight or glucose metabolism that cannot be discontinued or substituted, including antipsychotics (olanzapine, clozapine, quetiapine, etc.), valproate sodium, or lithium.\n21. History of alcohol abuse within 1 year prior to screening, defined as daily consumption \\>3 standard drink units (men) or \\>2 standard drink units (women) sustained for \\>3 months (1 standard drink unit ≈ 10g pure alcohol).","ALL","18 Years","75 Years",{"count":88,"type":89},150,"ESTIMATED","INTERVENTIONAL",[92],"PHASE4","Prediabetes affects millions of adults worldwide and carries a high risk of progression to type 2 diabetes. Mazdutide is a once-weekly injectable drug that activates both GLP-1 and glucagon receptors, lowering blood sugar and body weight simultaneously.\n\nThis study (DREAM-PRE) tests whether mazdutide can help adults with prediabetes return to normal blood sugar levels. Approximately 150 adults aged 18-75 years with prediabetes and BMI ≥22 kg\u002Fm² will be randomly assigned in equal numbers to one of three groups: mazdutide 4 mg once weekly, mazdutide 6 mg once weekly, or placebo once weekly. All participants also receive standardized diet and exercise guidance throughout the study.\n\nTreatment lasts 24 weeks, followed by 24 weeks of off-drug follow-up to see whether any benefits are maintained. The main question is: what proportion of participants achieve completely normal blood sugar (normal HbA1c, fasting glucose, AND glucose tolerance test) after 24 weeks of treatment? The study is conducted at approximately 10 hospitals across China.",[95,96,97],"Prediabetes","Impaired Fasting Glucose","Impaired Glucose Tolerance (Prediabetes)",[28,99,100,95,101,102,103,104,105],"IBI362","GLP-1R\u002FGCGR dual agonist","Diabetes prevention","Normal glucose regulation","Beta-cell function","Insulin resistance","Weight loss","NOT_YET_RECRUITING","2026-06-13",{"date":109,"type":110},"2026-06-17","ACTUAL",{"date":112,"type":89},"2026-07",{"date":114,"type":89},"2029-07",{"name":5,"class":6},1]